Update shared on04 Sep 2025
Given that both the consensus revenue growth forecast and future P/E remained steady, there has been no material change in analyst sentiment, resulting in the consensus price target for Aurobindo Pharma remaining unchanged at ₹1293.
What's in the News
- Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva Group for $5–5.5 billion from Advent International, which would be the largest-ever acquisition by an Indian pharma company; the acquisition would significantly boost Aurobindo’s footprint in the Eastern European market, especially in Czech Republic, Romania, and Slovakia (Key Developments).
- Shares of Aurobindo Pharma declined nearly 5% after reports surfaced regarding the potential Zentiva acquisition; the company issued a clarification stating that it routinely explores strategic opportunities but has not yet entered into any binding agreement, and called the news premature (Key Developments).
- Aurobindo Pharma’s Board scheduled a meeting on August 4, 2025, to consider the standalone and consolidated unaudited financial results for Q1 FY2025-26, as well as payment of an interim dividend (Key Developments).
- Aurobindo Pharma and its subsidiary Eugia reached a settlement agreement with Theravance Biopharma and Mylan regarding ongoing patent litigation over YUPELRI® (revefenacin) inhalation solution, granting Eugia a royalty-free license to launch its generic version in the US from April 23, 2039, subject to regulatory review (Key Developments).
- No notable periodical news directly referencing Aurobindo Pharma was identified in the provided sources.
Valuation Changes
Summary of Valuation Changes for Aurobindo Pharma
- The Consensus Analyst Price Target remained effectively unchanged, at ₹1293.
- The Consensus Revenue Growth forecasts for Aurobindo Pharma remained effectively unchanged, at 8.0% per annum.
- The Future P/E for Aurobindo Pharma remained effectively unchanged, at 20.77x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.